drugset / Trial / NCT07139353
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of linperlisib combined with chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma
Timeline
- Start
- 2025-09-15
- Primary completion
- 2027-09-01
- Completion
- 2029-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | 60 mg | Oral |
| Subject | Linperlisib | Small molecule | 80 mg | Oral |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |